372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

• Victoria Smith,
• Patrick Chun,
• Alexander Starodub,
• Sarina Piha-Paul,
• Raghad Karim,
• Michael Shafique,
• Gabriel Tinoco Suarez,
• Curtis Ruegg

Affiliations

Victoria Smith

1 Small Animal Hospital, Veterinary School, University of Glasgow, Glasgow, UK

Patrick Chun

6Amphivena Therapeutics, South San Francisco, CA, USA

Alexander Starodub

2Riverside Peninsula Cancer Institute, Goshen, IN, USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Raghad Karim

3NEXT Oncology, San Antonio, TX, USA

Michael Shafique

4Moffitt Cancer Center, Tampa, FL, USA

Gabriel Tinoco Suarez

5The Ohio State University, Columbus, OH, USA

Curtis Ruegg

6Amphivena Therapeutics, South San Francisco, CA, USA